Seagen

Youtube Subscribe

Open: 214.62 Close: 214.5 Change: -0.12

What an AI found about Seagen after reading the whole Internet.

How much time have you spent trying to decide whether investing in Seagen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Pfizer, …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Federal Trade Commission and European Commission are reviewing Pfizers planned $43 billion acquisition of cancer drug maker Seagen. Seagen expects to generate approximately $2.2 billion of revenue in 2023, representing 12 percent year-over-year growth.

Today's News

Creative Plannings holdings in Seagen were worth $2,297,000 at the end of the most recent quarter. Seagen had a negative return on equity of 26.46% and a negative net margin of 33.54%. Federal Trade Commission and European Commission are reviewing Pfizers planned $43 billion acquisition of cancer drug maker Seagen. Pfizer expected to certify compliance with FTC on Seagen deal in 2-3 weeks. Seagen Inc. (SGEN) , PFE. Pfizer confirmed plans to acquire Seagen, a smaller manufacturer focused on oncology medications. Pfizer agreed to pay $43 billion to acquire the cancer drug maker Seagen. Seagen has an analyst consensus of Moderate Buy, with a price target consensus. Bill Gross goes from Bond King to Merger-Arbitrage Player. Arb offers higher return, less downside if researched. Seagen expects to generate approximately $2.2 billion of revenue in 2023, representing 12 percent year-over-year growth. Seagen is an oncology industry leader in antibody-drug conjugate (ADC) technology.

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

The game is changing. There is a new strategy to evaluate Seagen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Pfizer, negative, return, Commission, plan, cancer, and the most common words in the summary are: seagen, job, manager, share, stock, inc, best, . One of the sentences in the summary was: Seagen expects to generate approximately $2.2 billion of revenue in 2023, representing 12 percent year-over-year growth.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #job #manager #share #stock #inc #best.

Read more →

Youtube Subscribe

---